Literature DB >> 14706339

Rhabdomyosarcoma development in mice lacking Trp53 and Fos: tumor suppression by the Fos protooncogene.

Alexander Fleischmann1, Wolfram Jochum, Robert Eferl, James Witowsky, Erwin F Wagner.   

Abstract

The Fos protein, a major component of the AP-1 transcription factor, is essential for osteoclast differentiation, acts as an oncogene, potentiates transforming signals, and controls invasive growth and angiogenesis during tumor progression. To investigate a potential genetic interaction between the Trp53 and Fos pathways, Trp53/Fos double knockout mice were generated. These mice develop highly proliferative and invasive rhabdomyosarcomas of the facial and orbital regions, with more than 90% penetrance at 6 months of age. Rhabdomyosarcoma cell lines established from the primary tumors express characteristic muscle-specific markers, and reexpression of Fos is associated with enhanced apoptosis in vitro. Moreover, Fos is able to repress Pax7 expression in rhabdomyosarcoma cell lines and primary myoblasts, suggesting a molecular link to genetic alterations involved in human rhabdomyosarcomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14706339     DOI: 10.1016/s1535-6108(03)00280-0

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  23 in total

Review 1.  Advances in pediatric rhabdomyosarcoma characterization and disease model development.

Authors:  D O'Brien; A G Jacob; S J Qualman; D S Chandler
Journal:  Histol Histopathol       Date:  2012-01       Impact factor: 2.303

Review 2.  Developmental origins of fusion-negative rhabdomyosarcomas.

Authors:  Ken Kikuchi; Brian P Rubin; Charles Keller
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

3.  Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.

Authors:  Marianna L Ianzano; Stefania Croci; Giordano Nicoletti; Arianna Palladini; Lorena Landuzzi; Valentina Grosso; Dario Ranieri; Massimiliano Dall'Ora; Ilaria Santeramo; Milena Urbini; Carla De Giovanni; Pier-Luigi Lollini; Patrizia Nanni
Journal:  Oncotarget       Date:  2014-01-15

Review 4.  Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.

Authors:  Venkatesh P Kashi; Mark E Hatley; Rene L Galindo
Journal:  Nat Rev Cancer       Date:  2015-07       Impact factor: 60.716

5.  Gammacoronavirus Avian Infectious Bronchitis Virus and Alphacoronavirus Porcine Epidemic Diarrhea Virus Exploit a Cell-Survival Strategy via Upregulation of cFOS to Promote Viral Replication.

Authors:  Li Xia Yuan; Jia Qi Liang; Qing Chun Zhu; Guo Dai; Shumin Li; To Sing Fung; Ding Xiang Liu
Journal:  J Virol       Date:  2020-11-25       Impact factor: 5.103

6.  Dystrophin and dysferlin double mutant mice: a novel model for rhabdomyosarcoma.

Authors:  Vishnu Hosur; Anoop Kavirayani; Jennifer Riefler; Lisa M B Carney; Bonnie Lyons; Bruce Gott; Gregory A Cox; Leonard D Shultz
Journal:  Cancer Genet       Date:  2012-05

7.  Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function.

Authors:  Charles Keller; Benjamin R Arenkiel; Cheryl M Coffin; Nabeel El-Bardeesy; Ronald A DePinho; Mario R Capecchi
Journal:  Genes Dev       Date:  2004-10-15       Impact factor: 11.361

8.  Prognostic significance of loss of c-fos protein in gastric carcinoma.

Authors:  Seon Pil Jin; Ji Hun Kim; Min A Kim; Han-Kwang Yang; Hee Eun Lee; Hye Seung Lee; Woo Ho Kim
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

9.  Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin.

Authors:  Lihua Min; Yuan Ji; Latifa Bakiri; Zhixin Qiu; Jin Cen; Xiaotao Chen; Lingli Chen; Harald Scheuch; Hai Zheng; Lunxiu Qin; Kurt Zatloukal; Lijian Hui; Erwin F Wagner
Journal:  Nat Cell Biol       Date:  2012-10-07       Impact factor: 28.824

Review 10.  Clinical relevance of molecular genetics to paediatric sarcomas.

Authors:  Olga Slater; Janet Shipley
Journal:  J Clin Pathol       Date:  2007-04-27       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.